Rosemary and Cancer: What Does the Science Say?

Rosemary contains several compounds that kill cancer cells in laboratory dishes and slow tumor growth in mice, but no human clinical trials have tested whether rosemary or its extracts can prevent or treat cancer in people. The research is almost entirely preclinical, meaning it comes from cell cultures and animal experiments. That gap between “kills cancer cells in a petri dish” and “helps a patient” is enormous, and it is the most important thing to understand about this topic. Still, the preclinical findings are genuinely interesting, and the way rosemary interacts with cooked food may offer a more grounded, practical connection to cancer risk.

The Compounds That Get the Attention

Rosemary is not one substance doing one thing. It is a complex mix of polyphenols, diterpenes, and triterpenes, and several of these have shown biological activity against cancer cells. The two found in the highest concentrations are carnosic acid and rosmarinic acid.¹ But they are far from alone. When researchers systematically tracked which components of rosemary extract actually contributed to killing colon cancer cells, they identified six active candidates, including carnosol, betulinic acid, and several less well-known diterpenes.²

This matters because it means rosemary’s anticancer effects in the lab probably come from multiple compounds working through different pathways, not from a single “magic ingredient.” It also means that different preparations of rosemary, whether a standardized extract, a supercritical fluid extraction, or a sprig thrown into a roasting pan, will contain these compounds in very different ratios. Any two rosemary studies may not be testing quite the same thing.

What Happens in Lab Studies

The cell-culture research is extensive and shows activity against a range of cancer types. The mechanisms researchers have documented fall into a few broad categories.

One recurring finding involves reactive oxygen species, or ROS. These are chemically reactive molecules that, in high enough concentrations, damage cells and trigger programmed cell death. Carnosic acid ramps up ROS production inside cancer cells. In breast cancer cell lines, treatment with carnosic acid caused a roughly threefold increase in ROS levels, and when researchers added an antioxidant to neutralize the ROS, the cancer-killing effect disappeared.³ The same pattern showed up in colon cancer cells: blocking ROS rescued the cells from carnosic acid-induced death.⁴

There is an irony here worth noting. Rosemary is widely known as an antioxidant, yet its anticancer activity in the lab works partly by increasing oxidative stress inside tumor cells. The explanation researchers have offered is that cancer cells often have different redox states than normal cells, making them more vulnerable to a sudden surge in ROS. Whether that selectivity holds up outside a dish is another question entirely.

Rosemary compounds also block inflammatory signaling pathways. Rosemary extract inhibited the NF-kB pathway, a central switch in inflammation that many cancers hijack to promote their own survival and growth.⁵ Multiple compounds in the extract appear to contribute: ursolic acid blocks NF-kB phosphorylation, and carnosol does something similar.⁶ A 2020 review summarized the overall picture: rosemary’s antitumor activity has been linked to antioxidant effects, anti-inflammatory responses, blocking the growth of new blood vessels that feed tumors, epigenetic changes, and the activation of tumor-suppressor genes.⁷

Which Cancer Types Have Been Studied

The research is not confined to one or two cancers. Lab studies have tested rosemary compounds against colon, breast, prostate, and blood cancers, among others.

Colon cancer is probably the most thoroughly studied. Rosemary extract reduced cell migration and colony formation in three different colon cancer cell lines, suggesting it could theoretically limit both tumor growth and the spread of cancer to other sites.⁸ One transcriptomic study found that rosemary polyphenols altered the expression of roughly four percent of all genes in colon cancer cells, but the specific genes affected differed markedly between two colon cancer cell lines, suggesting the extract’s effects depend on the tumor’s particular genetic makeup.⁹

In breast cancer, rosemary extract inhibited proliferation and survival of triple-negative breast cancer cells, a particularly aggressive subtype with limited treatment options, in a dose-dependent manner.¹⁰ Carnosic acid also appears to affect estrogen-receptor-negative cells specifically, with evidence that it selectively targets cells with high levels of the HER2 receptor.¹¹ A separate study found that a rosemary fraction could downregulate both estrogen receptors and HER2 receptors in breast cancer cells from different tumor subtypes, which could theoretically make those cells more vulnerable.¹²

For prostate cancer, standardized rosemary extract promoted the breakdown of the androgen receptor, a protein that drives the growth of most prostate cancers. In a mouse xenograft model, oral rosemary extract suppressed tumor growth by about 46%.¹³ Carnosic acid specifically was shown to bind the androgen receptor and trigger its destruction through a stress-response pathway inside cells, reducing xenograft prostate tumor growth by about 53% in a separate study.¹⁴

Blood cancers have received less attention, but the results are noteworthy. Carnosol triggered cell death in several acute lymphoblastic leukemia cell lines by reducing levels of Bcl-2, a protein that helps cancer cells resist death.¹⁵ In adult T-cell leukemia/lymphoma cells, carnosol induced cell death through a different route: depleting glutathione, a molecule cells rely on to manage their internal chemistry.¹⁶ Carnosol’s chemopreventive potential has been confirmed across multiple cell culture and animal experiments.¹⁷

The Bioavailability Problem

A compound that kills cancer cells in a dish only matters if it can actually reach a tumor inside a living body. This is where the research becomes more sobering. In rats given carnosic acid orally, the bioavailability was about 40%, meaning roughly that proportion made it into the bloodstream. Traces were found in the liver and muscle tissue, and the main elimination route was through feces.¹⁸ Forty percent bioavailability sounds respectable, but there is a catch: carnosic acid is metabolically unstable. It gets rapidly transformed in the body through oxidation, glucuronidation, and methylation, producing a large array of metabolites.¹⁹ Whether those metabolites retain any anticancer activity is largely unknown.

For colon cancer specifically, there may be a partial workaround. Some rosemary compounds that are not absorbed in the small intestine, particularly certain triterpenes and diterpenes, travel to the large intestine where they could interact directly with colon tissue and gut bacteria.²⁰ This means that for colon cancer, the unabsorbed fraction might be doing something useful rather than going to waste. But for cancers elsewhere in the body, the question of whether enough active compound reaches the tumor site at a high enough concentration remains unanswered in humans.

The Rosemary-in-Cooking Angle

While the therapeutic use of rosemary against existing cancers remains speculative, there is a more immediate and practical connection between rosemary and cancer risk: what happens when you cook meat with it. High-temperature cooking of meat produces heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs), both of which are recognized carcinogens. Rosemary appears to substantially reduce the formation of these compounds.

When ethanolic rosemary extract was added to beef patties cooked at high temperatures, the most effective formulation reduced MeIQx, one of the most common HCAs, by up to about 92% and PhIP, another major HCA, by up to about 85%.²¹ An earlier study using rosemary powder and rosmarinic acid found reductions in the 50-77% range depending on the compound and cooking conditions, with larger effects at higher temperatures and longer cooking times, precisely the situations where HCA formation is worst.²² A study on fried pork balls found that adding 0.25% rosemary reduced total HCA content by about 59% and PAH content by about 30%.²³

This is arguably the most actionable finding in the entire rosemary-cancer literature. You do not need a clinical trial to decide whether to add rosemary to a marinade. The mechanism is straightforward: rosemary’s antioxidant compounds interfere with the chemical reactions that produce HCAs and PAHs during high-heat cooking. The effect is robust across multiple studies, multiple meat types, and multiple forms of rosemary. If you regularly grill, fry, or broil meat, adding rosemary to your preparation is a low-cost, low-risk way to reduce your exposure to known carcinogens.

Gut Microbiome Effects

A newer line of research connects rosemary compounds to cancer through the gut microbiome. In a mouse model of colorectal cancer, carnosic acid shifted the composition of gut bacteria, which in turn changed the production of certain metabolites including lactic acid. These changes appeared to suppress a key inflammatory signaling molecule, IL-17, through the NF-kB/STAT3 pathway, reducing tumor burden.²⁴ This is a single animal study and should be interpreted cautiously, but it raises an interesting possibility: some of rosemary’s effects on colon cancer may be indirect, mediated through changes in the microbial community rather than through direct contact with cancer cells.

Safety and Drug Interactions

Rosemary as a culinary herb has a long safety record, but concentrated rosemary extracts and supplements are a different story. A comprehensive review of rosemary toxicity and safety emphasized the importance of considering drug interactions when using rosemary in concentrated forms.²⁵

One specific concern is how rosemary compounds interact with the liver enzymes responsible for processing medications. Carnosol was found to inhibit certain CYP450 enzymes and modulate metabolic transporters in lab assays.²⁶ These are the same enzyme families that process many prescription drugs, including some chemotherapy agents. If you are taking rosemary supplements alongside cancer treatment, there is at least a theoretical risk that the supplement could alter how your body handles the medication, either making it less effective or increasing side effects. This is not a proven problem in humans yet, but the mechanistic basis for concern is there, and anyone undergoing cancer treatment should discuss supplements with their oncologist before adding them.

Why There Are No Human Cancer Trials

Given decades of promising lab results, the obvious question is why nobody has run a clinical trial in cancer patients. Several factors explain the gap. Rosemary is a common plant, and its active compounds are not patentable in their natural form, which limits the financial incentive for pharmaceutical companies to fund expensive human trials. The extract is also a complex mixture, making it difficult to standardize doses across study sites. Every batch of rosemary extract can differ in its ratio of active compounds depending on the plant variety, growing conditions, and extraction method used.

There are also basic scientific hurdles. The concentrations of carnosic acid or carnosol used in cell-culture studies are often far higher than what you could plausibly achieve in human blood through oral supplementation, especially given how quickly these compounds are metabolized. Animal studies used xenograft tumors, human cancer cells implanted under the skin of mice, which do not perfectly model how tumors behave in human organs with an intact immune system and complex blood supply. These models are a reasonable starting point, but many compounds that shrink xenograft tumors in mice fail completely in human trials.

None of this means rosemary is useless against cancer. It means the evidence has not been tested at the level that matters most. The lab findings are consistent and come from many independent groups working on different cancer types, which gives them more weight than a single flashy result. But “consistent preclinical findings” has been the description of thousands of natural compounds that ultimately did not translate into human therapies. Being honest about that track record is more useful than overselling the data.

Rosemary Supplements Versus Culinary Use

The distinction between eating rosemary as a food and taking it as a concentrated supplement matters for how you interpret the research. Culinary use provides low doses of the active compounds along with food, and it has the practical benefit of reducing carcinogen formation during cooking, as described earlier. Concentrated extracts and supplements deliver far higher doses, closer to what is used in lab studies, but they also carry more risk of drug interactions and potential side effects.

If your interest is general cancer risk reduction, the strongest evidence-based action involving rosemary is using it in meat marinades and rubs before high-heat cooking. That approach has been validated in multiple food-science studies, it reduces exposure to known carcinogens, and it involves no supplements or unusual doses. If your interest is using rosemary as a complement to cancer treatment, the honest scientific answer right now is that there is not enough human evidence to support that use, and the potential for drug interactions makes it something to approach carefully and only with medical guidance.